RBC Rainbow Babies & Childrens (0 mi.)
11100 Euclid Ave
Cleveland, OH 44106
DO 5850 Landerbrook (7 mi.)
5850 Landerbrook Dr
Mayfield Heights, OH 44124
UH Broadview Heights Health Center (13 mi.)
5901 E Royalton Rd
Broadview Heights, OH 44147
UH Westlake Health Center (15 mi.)
960 Clague Rd
Westlake, OH 44145
RBC Perrico (15 mi.)
4176 State Route 306
Willoughby, OH 44094
UH North Ridgeville Health Center (21 mi.)
32800 Lorain Rd
North Ridgeville, OH 44039
Biography: James Strainic, MD
- Assistant Professor, CWRU School of Medicine
Fellowship | Pediatric Cardiology
Pediatric Cardiology - Uh Case Medical Center (2006 - 2009)
Residency | Pediatrics/Chief Resident
Pediatrics/Chief Resident - University Hospitals Of Cleveland (2005 - 2006)
Residency | Pediatrics
Pediatrics - University Hospitals Of Cleveland (2002 - 2005)
University Of Cincinnati College Of Medicine (1998 - 2002)
Xavier University (1998)
James Strainic, MD, is a pediatric cardiologist and director of the Fetal Heart Program in the Congenital Heart and Director of Pediatric Cardiology Outpatient Services at the Congenital Heart Collaborative at University Hospitals Rainbow Babies & Children’s Hospital.
As director of the Fetal Heart Program, Dr. Strainic oversees all aspects of maternal-fetal cardiology care at UH Rainbow Babies & Children’s Hospital. The fetal heart center offers fetal cardiology diagnostic imaging and fetal cardiac intervention. The fetal cardiac intervention team is a 12-member team, representing obstetrics & gynecology, maternal fetal medicine, pediatric cardiology, pediatric interventional cardiology, pediatric anesthesia, OB anesthesia from UH Rainbow, Nationwide Children’s Hospital and MacDonald Women’s Hospital, that performs fetal aortic valvuloplasty. This fetal heart program is the only one in Ohio to offer fetal aortic valvuloplasty and one of only in 10 in the nation. The team provides advanced care locally in north east Ohio and internationally with patients coming as far as the United Arab Emirates.
Critical to infants with developing congenital heart disease, fetal aortic valvuloplasty is a unique procedure that uses ultrasound guidance and a catheter-based approach to gain access to the fetal heart, subsequently opening the aortic valve using a tiny, inflated balloon. This increases blood flow through the left ventricle of the heart to help its development and prevent the progression of hypoplastic left heart syndrome (HLHS). The goal of the minimally invasive fetal procedure is to attempt to reverse the developing HLHS and decrease the number of open heart surgeries for the child later in life – or eliminate them entirely.
Dr. Strainic is also an assistant professor at Case Western Reserve University School of Medicine. He earned his undergraduate degree in natural sciences at Xavier University in Cincinnati and his medical degree at University of Cincinnati College of Medicine. He completed his residency training in pediatrics and fellowship training in pediatric cardiology at UH Rainbow Babies & Children’s Hospital.
Dr. Strainic is active in the field of pediatric cardiology research. His published work includes peer-reviewed journal articles, abstracts and book chapters and he has presented at international, national and regional medical conferences and meetings.
Related Blog Articles
While it can often go undetected until a severe issue occurs, there are steps parents can take to reduce the risk of SCA.
After a heart abnormality was discovered in baby Emmett’s first ultrasound, fetal heart intervention was used to give him “the healthiest heart and best outlook possible.”
Dr. Doaa was halfway through her pregnancy and living out of the country when her doctor told her and her husband that there was a serious problem with her baby’s heart and there was nothing they could do.
You have already counted each tiny finger and toe. A simple, painless test can make sure your baby’s heart is healthy, too.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, James Strainic did not disclose any Outside Relationships with Industry.